keyword
MENU ▼
Read by QxMD icon Read
search

Progression-free survival

keyword
https://www.readbyqxmd.com/read/28820306/prognostic-value-of-estrogen-receptor-in-who-grade-iii-meningioma-a-long-term-follow-up-study-from-a-single-institution
#1
Lingyang Hua, Hongda Zhu, Jingrun Li, Hailiang Tang, Dapeng Kuang, Yin Wang, Feng Tang, Xiancheng Chen, Liangfu Zhou, Qing Xie, Ye Gong
OBJECTIVE Malignant meningioma is rare and classified as Grade III in the WHO classification of CNS tumors. However, the presence of estrogen receptor (ER) in WHO Grade III meningiomas and its correlation with patients' outcomes are still unclear. In this single-center cohort study, the authors analyzed clinical features, treatment, and prognosis of these malignant tumors in patients with long-term follow-up. METHODS A total of 87 patients who were pathologically diagnosed with WHO Grade III meningiomas between 2003 and 2008 were enrolled in this study and followed for at least 7 years...
August 18, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28820285/oligometastatic-cancer-stereotactic-ablative-radiotherapy-for-patients-affected-by-isolated-body-metastasis
#2
Andrea Lancia, Gianluca Ingrosso, Alessandra Carosi, Luana Di Murro, Emilia Giudice, Sara Cicchetti, Pasquale Morelli, Daniela di Cristino, Claudia Bruni, Alessandra Murgia, Alessandro Cancelli, Irene Turturici, Anjali Iadevaia, Elisabetta Ponti, Riccardo Santoni
BACKGROUND: To evaluate the outcome of patients affected by a single isolated body metastasis treated with stereotactic body radiotherapy (SBRT). MATERIAL AND METHODS: Seven-eight patients were treated with SBRT for isolated body metastasis. The most frequent primary tumor was prostate cancer (28.2%), followed by colorectal cancer (23.1%) and lung cancer (20.5%). Median age at diagnosis of oligometastatic disease was 70 years (range 47-88). Median Karnofsky Performance Status (KPS) was 90 (range 70-100)...
August 18, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28819729/prognostic-significance-of-cdx2-immunoexpression-in-poorly-differentiated-clusters-of-colorectal-carcinoma
#3
Luca Reggiani Bonetti, Simona Lionti, Enrica Vitarelli, Valeria Barresi
CDX2 is a transcription factor that acts as a tumor suppressor in colorectal cancer (CRC). Its loss triggers metastatic process and tumor progression; however, its prognostic role in patients with CRC is still controversial. Poorly differentiated clusters (PDCs) are aggregates of neoplastic cells which likely have high metastatic potential in CRC. In this study, we analyzed and compared CDX2 expression in PDC (CDX2-PDC) and corresponding main tumor (CDX2 main tumor) in 42 CRCs showing at least 10 PDC (PDC G3)...
August 17, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28819727/abiraterone-acetate-a-review-in-metastatic-castration-resistant-prostrate-cancer
#4
Lesley J Scott
Oral abiraterone acetate (Zytiga(®)) is a selective inhibitor of CYP17 and thereby inhibits androgen biosynthesis, with androgen signalling crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently, in the development of metastatic castration-resistant PC (mCRPC). In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in combination with prednisone was an effective treatment and had an acceptable, manageable tolerability and safety profile in chemotherapy-naive and docetaxel-experienced men with mCRPC...
August 17, 2017: Drugs
https://www.readbyqxmd.com/read/28819719/activity-of-cabazitaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-after-treatment-with-single-or-dual-regimens-of-novel-androgen-receptor-targeting-agents
#5
Yukari Bando, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
The purpose of this study was to evaluate the efficacy of cabazitaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) after sequential therapy with docetaxel (DTX) and single or dual regimens of novel androgen receptor-axis-targeted (ARAT) agents. We retrospectively reviewed 84 consecutive patients treated with cabazitaxel at Kobe University Hospital and related hospitals from September 2014 to September 2016. The association of each prognostic parameter with progression-free survival (PFS) was evaluated, including the sequence of therapy...
August 17, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28819445/dna-dependent-protein-kinase-catalytic-subunit-functions-in-metastasis-and-influences-survival-in-advanced-stage-laryngeal-squamous-cell-carcinoma
#6
Sha-Sha He, Yong Chen, Xiao-Ming Shen, Hong-Zhi Wang, Peng Sun, Jun Dong, Gui-Fang Guo, Ju-Gao Chen, Liang-Ping Xia, Pei-Li Hu, Hui-Juan Qiu, Shou-Sheng Liu, Yi-Xin Zhou, Wei Wang, Wei-Han Hu, Xiu-Yu Cai
Background: DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is known to function in several types of cancer. In this study, we investigated the expression and clinicopathologic significance of DNA-PKcs in laryngeal squamous cell carcinoma (LSCC). Methods: We conducted a retrospective study of 208 patients with advanced-stage LSCC treated at Sun Yat-sen University Cancer Center, Guangzhou, China. We assessed DNA-PKcs and p16INK4a (p16) status using immunohistochemistry. We examined the association between DNA-PKcs expression and clinicopathologic features and survival outcomes...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819438/elevated-expression-of-derlin-1-associates-with-unfavorable-survival-time-of-squamous-cell-carcinoma-of-the-head-and-neck-and-promotes-its-malignance
#7
Leiming Pi, Gangcai Zhu, Li She, Ming Wei, Guancheng Liu, Changhan Chen, Di Hu, Fusen Peng, Haolei Tan, Yong Liu, Donghai Huang, Yongquan Tian, Xin Zhang
Derlin-1 is over-expressed to function as an oncoprotein in breast, lung and colon cancers. However, the implications of Derlin-1 involved in squamous cell carcinoma of the head and neck (SCCHN) remain unknown. This study aims to investigate the effects of Derlin-1 expression on SCCHN tissues and cells. The potential mechanism of Derlin-1 regulating SCCHN cell proliferation, apoptosis and metastasis was also indicated in this work. Western blot and immunohistochemistry (IHC) assays showed that Derlin-1 was over-expressed in 114 SCCHN samples and five SCCHN cell lines...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819417/mdm2-snp309-and-snp285-act-as-negative-prognostic-markers-for-non-small-cell-lung-cancer-adenocarcinoma-patients
#8
Christophe Deben, Ken Op de Beeck, Jolien Van den Bossche, Julie Jacobs, Filip Lardon, An Wouters, Marc Peeters, Guy Van Camp, Christian Rolfo, Vanessa Deschoolmeester, Patrick Pauwels
Objectives: Two functional polymorphisms in the MDM2 promoter region, SNP309T>G and SNP285G>C, have been shown to impact MDM2 expression and cancer risk. Currently available data on the prognostic value of MDM2 SNP309 in non-small cell lung cancer (NSCLC) is contradictory and unavailable for SNP285. The goal of this study was to clarify the role of these MDM2 SNPs in the outcome of NSCLC patients. Materials and Methods: In this study we genotyped SNP309 and SNP285 in 98 NSCLC adenocarcinoma patients and determined MDM2 mRNA and protein levels...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819412/ct-guided-125-i-brachytherapy-for-locally-recurrent-nasopharyngeal-carcinoma
#9
Huzheng Yan, Zhiqiang Mo, Zhanwang Xiang, Dailin Rong, Yanlin Zhang, Guanyu Chen, Zhihui Zhong, Fujun Zhang, Fei Gao
Purpose: The study evaluated the feasibility, clinical effectiveness, and quality of life of computed tomography (CT)-guided (125)I brachytherapy for locally recurrent nasopharyngeal carcinoma (NPC). Methods: We recruited 81 patients diagnosed with locally recurrent NPC after previous radiotherapy with or without chemotherapy. Thirty-nine patients received (125)I brachytherapy (group A) and 42 received re-irradiation (IMRT, group B). The evaluated outcomes were local control, complications, and quality of life...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819405/linc00152-promotes-cancer-cell-proliferation-and-invasion-and-predicts-poor-prognosis-in-lung-adenocarcinoma
#10
Pei-Pei Zhang, Yi-Qin Wang, Wei-Wei Weng, Wei Nie, Yong Wu, Yu Deng, Ping Wei, Mi-Die Xu, Chao-Fu Wang
Background: The long non-coding RNA Linc00152 stimulates tumor progression in cancer. However, its clinical significance and biological functions in lung adenocarcinoma remains unknown. We evaluate the expression of Linc00152 in lung adenocarcinoma and its possible correlation with clinicopathologic features and patient survival to reveal its biological effects in cancer progression and prognosis. Methods: Total RNA extraction was performed on 110 pairs of lung adenocarcinoma and adjacent normal tissue samples, and then RT-qPCR was conducted...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819398/clinical-impact-of-vitamin-k-dosing-on-sorafenib-treatment-for-hepatocellular-carcinoma
#11
Yoshimichi Haruna, Noriko Hasegawa, Kazuho Imanaka, Seiichi Kawamoto, Atsuo Inoue
Background: Some researchers have suggested that vitamin K enhances the antitumor effect of sorafenib for hepatocellular carcinoma (HCC) in vitro and in vivo. In this study, we examined the clinical impact of vitamin K dosing for sorafenib treatment. Methods: Twenty-nine out of 65 patients treated with sorafenib for HCC were simultaneously dosed with vitamin K. We retrospectively investigated progression-free survival (PFS) and overall survival (OS) in the vitamin K-dosed group and sorafenib alone group. We also examined the changes in serum des-γ-carboxy prothrombin (DCP) levels, which vitamin K is involved with...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819385/a-randomized-open-label-safety-and-exploratory-efficacy-study-of-kanglaite-injection-klti-plus-gemcitabine-versus-gemcitabine-in-patients-with-advanced-pancreatic-cancer
#12
Lee S Schwartzberg, Francis P Arena, Bryan J Bienvenu, Edward H Kaplan, Luis H Camacho, Luis T Campos, J Paul Waymack, Mary A Tagliaferri, Michael M Chen, Dapeng Li
Background: This study was designed to assess the safety and preliminary efficacy of KLTi plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Methods: In a randomized, open-label study, patients with locally advanced or metastatic pancreatic cancer were randomized 2:1 to receive KLTi plus gemcitabine or gemcitabine monotherapy. Three sequential cohorts were tested at 30 g/day, 50 g/day, and 30 g/day. Gemcitabine was administered at 1000 mg/m(2) on days 1, 8 and 15 of each 28 day cycle...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819384/the-comparison-of-egfr-tki-failure-modes-and-subsequent-management-between-exon-19-deletion-and-exon-21-l858r-mutation-in-advanced-non-small-cell-lung-cancer
#13
Yaxiong Zhang, Gang Chen, Xi Chen, Wenfeng Fang, Fei Gao, Yunpeng Yang, Yuanyuan Zhao, Yuxiang Ma, Shaodong Hong, Zhonghan Zhang, Siyu Miao, Manli Wu, Xiaodan Huang, Youli Luo, Cong Zhou, Run Gong, Yan Huang, Likun Chen, Ningning Zhou, Hongyun Zhao, Li Zhang
Background: Advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19 Del) and exon 21 L858R mutation (L858R) might be distinct diseases. Therefore, it is necessary to take EGFR mutation subgroups into consideration for making choices of subsequent treatment after tyrosine kinase inhibitors (TKIs) failure. Patients and methods: 174 patients who developed to EGFR-TKI failure were categorized into three cohorts of dramatic progression, gradual progression and local progression...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819093/non-seminomatous-germ-cell-tumor-presenting-with-superior-vena-cava-syndrome
#14
Paolo K Soriano, Muhammad F Iqbal, Omar M Siddiqui, Jeff F Wang, Meghna R Desai
BACKGROUND Primary mediastinal non-seminomatous germ cell tumors (NSGCTs) are aggressive and carry a poor five-year disease free survival rate even with aggressive treatment. We describe a young adult male with primary mediastinal NSGCT presenting with airway obstruction and superior vena cava syndrome (SVCS). CASE REPORT The patient presented with four weeks of nonproductive cough, weight loss, and right-sided pleuritic chest pain. Chest computed topography (CT) imaging demonstrated a right-sided mediastinal mass determined as a yolk sac tumor on biopsy...
August 18, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28818987/response-assessment-of-68-ga-dota-e-c-rgdfk-2-pet-ct-for-lung-adenocarcinoma-patients-treated-with-nintedanib-plus-docetaxel
#15
Oscar Arrieta, Francisco O Garcia-Perez, David Michel-Tello, Laura-Alejandra Ramirez-Tirado, Quetzali Pitalua-Cortes, Graciela Cruz-Rico, Eleazar-Omar Macedo-Perez, Andres F Cardona, Jaime de la Garza-Salazar
Nintedanib is an oral angiokinase inhibitor used as a second-line treatment for non-small-cell lung cancer (NSCLC). New radiotracers, such as (68)Ga-DOTA-E-[c(RGDfK)]2, that target αvβ3 integrin might impact the clinical practice as a non-invasive method for assessing angiogenesis inhibitors. Methods: From July 2014 through October 2015, 38 patients received second-line nintedanib plus docetaxel. All the patients underwent PET/CT with (68)Ga-DOTA-E-[c(RGDfK)]2 radiotracer and blood-sample tests to quantify angiogenesis factors (FGF, VEGF and PDGF-AB) prior to and after completing 2 therapy cycles...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818550/perinephric-and-sinus-fat-invasion-in-stage-pt3a-tumors-managed-by-partial-nephrectomy
#16
Pascal Mouracade, Julien Dagenais, Jaya Sai Chavali, Onder Kara, Ryan J Nelson, Matthew J Maurice, Jeremy Reese, Brian I Rini, Jihad H Kaouk
INTRODUCTION: We evaluated the influence of perinephric fat invasion (PFI) compared with sinus fat invasion (SFI) on disease-free survival (DFS) and cancer-specific survival (CSS) after partial nephrectomy (PN) for stage pT3a renal cell carcinoma (RCC). MATERIALS AND METHODS: Data were recorded from the consecutive records of patients who had undergone underwent PN for cT1-T2 RCC from 2007 to 2016. Of these patients, 143 had stage pT3a with SFI or PFI found on final pathologic examination...
July 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28818526/which-patients-with-upper-tract-urothelial-carcinoma-can-be-safely-treated-with-conservative-treatment-by-flexible-ureteroscopy-with-holmium-yag-laser-photoablation-long-term-results-from-a-high-volume-institution
#17
Luca Villa, Mattieu Haddad, Umberto Capitanio, Bhaskar K Somani, Jonathan Cloutier, Steeve Doizi, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Olivier Traxer
PURPOSE: To test the effects of tumour size, tumour distribution and tumour grade on progression-free survival (PFS) in patients with upper tract urothelial carcinoma (UTUC) treated with flexible ureteroscopy with Holmium:YAG laser photoablation (FULP). MATERIALS AND METHODS: Data from 92 consecutive UTUC patients treated with FULP (2003-2015) at a single tertiary care referral center were included. A stringent follow-up was offered according to the European Association Urological guidelines...
August 14, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28818493/progression-free-survival-and-time-to-progression-as-real-surrogate-end-points-for-overall-survival%C3%A2-in-advanced-breast-cancer-a-meta-analysis-of-37-trials
#18
Ling Li, Zhanyu Pan
BACKGROUND: Progression-free survival (PFS) and time to progression (TTP) have been reported to correlate with overall survival (OS) in several cancer types. To our knowledge, however, the correlation between them is unclear. METHODS: A literature-based meta-analysis was performed to assess whether PFS and TTP can be considered reliable surrogate end points for OS in a phase 3 clinical trial of advanced breast cancer (ABC). The median hazard ratios of PFS/TTP and OS were analyzed by determining their nonparametric Spearman rank correlation coefficients (Rs)...
July 25, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28818355/ar-v7-in-peripheral-whole-blood-of-patients-with-castration-resistant-prostate-cancer-association-with-treatment-specific-outcome-under-abiraterone-and-enzalutamide
#19
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott, Sebastian Schmid, Ramona Secci, Margitta Retz, Jürgen E Gschwend, Jürgen Ruland, Christof Winter, Matthias M Heck
BACKGROUND: It has been demonstrated that androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells (CTCs) predicts poor treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide. OBJECTIVE: To develop a practical and robust liquid profiling approach for direct quantification of AR-V7 in peripheral whole blood without the need for CTC capture and to determine its potential for predicting treatment response in mCRPC patients...
August 14, 2017: European Urology
https://www.readbyqxmd.com/read/28817838/pharmacogenetic-determinants-of-outcomes-on-triplet-hepatic-artery-infusion-and-intravenous-cetuximab-for-liver-metastases-from-colorectal-cancer-european-trial-optiliv-nct00852228
#20
Francis Lévi, Abdoulaye Karaboué, Raphaël Saffroy, Christophe Desterke, Valerie Boige, Denis Smith, Mohamed Hebbar, Pasquale Innominato, Julien Taieb, Carlos Carvalho, Rosine Guimbaud, Christian Focan, Mohamed Bouchahda, René Adam, Michel Ducreux, Gérard Milano, Antoinette Lemoine
BACKGROUND: The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer. This planned study aimed at the identification of pharmacogenetic predictors of outcomes. METHODS: Circulating mononuclear cells were analysed for 207 single-nucleotide polymorphisms (SNPs) from 34 pharmacology genes...
August 17, 2017: British Journal of Cancer
keyword
keyword
119233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"